Revelation Biosciences, Inc.
REVBNASDAQHealthcareBiotechnology
Previous close
$1.09
$0.00 · 0.00%
REVB company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
50
Fair Value
Momentum
24
Weakening
Sentiment
57
Mixed
Risk resilience
31
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteRevelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- James Rolke
- Listed since
- Nov 17, 2020
- Employees
- 8
Market position
Day range
Current $1.09
52-week range
Current $1.09
- Open
- $1.10
- Previous close
- $1.09
- Volume
- 9.06K
- 0.17× average
- Average volume
- 53.77K
- Average daily volume
- Market cap
- 4.26M USD
- Beta
- -0.17
- Market reference 1
- 50-day average
- $1.0573
- +3.09% above average
- 200-day average
- $1.8805
- -42.04% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -7.97M USD
- EV / EBITDA
- 0.88×
- Earnings yield
- -448.70%
- Free cash flow yield
- -416.28%
Profitability & efficiency
- Return on equity
- -100.59%
- Return on assets
- -76.96%
- Return on invested capital
- -94.41%
Financial health
- Current ratio
- 5.41×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 27.06K USD | 27.92K USD | 25.05K USD | 40.01K USD | — |
| Gross profit | −27.06K USD | −27.92K USD | −25.05K USD | −40.01K USD | — |
| Research and development | 4.06M USD | 3.55M USD | 4.15M USD | 5.38M USD | 6.91M USD |
| Selling, general, and administrative | 5.01M USD | 4.43M USD | 4.51M USD | 5.49M USD | 5.04M USD |
| Operating expenses | 9.07M USD | 7.98M USD | 8.66M USD | 10.86M USD | 11.95M USD |
| Interest expense | — | — | — | — | 41.76K USD |
| Depreciation and amortization | 27.06K USD | 27.92K USD | 25.05K USD | 25.05K USD | 16.78K USD |
| Operating income | −9.07M USD | −7.98M USD | −8.66M USD | −10.86M USD | −11.95M USD |
| Net income | −8.91M USD | −15.04M USD | −120.25K USD | −10.83M USD | −11.99M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 27%
- 3 beats, 8 misses, 0 met estimates
- Average EPS surprise
- -3541.18%
- 11 comparable reports
- Latest EPS result
- -0.87
- Estimate -0.88 · Beat by 0.57%
EPS: actual versus estimate
Recent quarterly results
REVB peers
Continue in GoAI
Research REVBresearch.disclaimer